angina pectoris
Conditions
Interventions
Alirocumab 75mg/2week+Rosuvastatin 5mg/daily during 9 months
Rosuvastatin 10mg/daily alone during 9 months
Sponsors
Kobe University,department of cardiology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: In patients undergoing PCI with ACS or stable angina, stenosis of 25-75% on CAG remained after PCI and maxLCBI(4mm) was over 400 in patients who could analyze NIRS-IVUS images.
Exclusion criteria
Exclusion criteria: Patients who have received one or more doses of anti-PCSK9 monoclonal antibody. Patients who experienced poorly controlled high blood pressure (systolic blood pressure>180 mmHg or diastolic blood pressure>110 mmHg measured more than once) between the time of PCI and randomization. Patients with LDL-Chol value <70 mg/dl. Patients with allergic drug hypersensitivity to drugs to be used. Patients with a history of hemorrhagic stroke. Patients receiving treatment for anticancer drugs. Patients undergoing LDL apheresis. Patients with serious liver and kidney dysfunction. Patients who conflict with any of the warning contraindications listed in the Rosuvastatin national package insert. Patients contradicting the contraindications listed in the Pralient's national package insert. Pregnant women and pregnant or lactating patients. Others Patients judged inappropriate by the doctor in charge of this exam.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We investigate the change in the maxLCBI (4 mm) value calculated by NIRS-IVUS test at the time of PCI and treatment evaluation (week 36) in the group of Alirocumab and standard treatment (statin alone). | — |
Secondary
| Measure | Time frame |
|---|---|
| LCBI(lesion), Angle of lipid core, EEM CSA, Lumen CSA, Minimum lumen diameter, Plaque burden, Lesion length | — |
Countries
Japan
Contacts
Public ContactTanimura Kosuke
Kobe University Hospital Cardiology
Outcome results
None listed